MedPath

To study levels of calcium, phosphorous and vitamin in body fluids before and after a 12 weeks course of pioglitazone, an anti diabetic agent, in pateints with diabetes

Not Applicable
Conditions
Health Condition 1: null- type 2 diabetes
Registration Number
CTRI/2012/04/002597
Lead Sponsor
RSSDI
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Other (Terminated)
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

Patients attending diabetic clinic or endocrine out patient department (OPD) services of SSKM Hospital and IPGMER will be considered. Patients of type 2 diabetes not controlled (fasting sugar >110, Post prandial > 180 or HbA1C >6.5) on medical nutrition therapy and metformin would be undertaken for the study

Exclusion Criteria

1)Patients with very poorly controlled sugars i.e. HbA1C more than 8 will not be enrolled since glycosuria is associated with hypercaiciuria and control of glycemic status with pioglitazone can decrease calcium excretion and confound results

2)Patients taking insulin and/or other anti-diabetic drugs will be excluded. Patients on ACE inhibitors and diuretics will be excluded as will patients having blood pressures above 180systolic or diastolic above 110 mm Hg

3)Also patients with associated disorders like primary hyperparathyroidism, chronic kidney disease, liver disease, any chronic illness, malignancy, chronic drug use like anti-epileptic agents, oral contraceptive pills, steroids which are likely to interfere with vitamin-D metabolism will be excluded.

4)Patients with pregnancy would be excluded. Patients on calcium or vitamin-D supplementation would also be excluded.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1) effect on urinary calcium and phosphate excretion <br/ ><br>2) effect on serum vitamin D and 1,25 vitamin D levelsTimepoint: 1) effect on urinary calcium and phosphate excretion <br/ ><br>2) effect on serum vitamin D and 1,25 vitamin D levels
Secondary Outcome Measures
NameTimeMethod
effect on glycemic controlTimepoint: 3 months
© Copyright 2025. All Rights Reserved by MedPath